Xenetic Biosciences Statistics Share Statistics Xenetic Biosciences has 1.54M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 1.54M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 3.8% Shares Floating 1.25M Failed to Deliver (FTD) Shares 223 FTD / Avg. Volume 0.28%
Short Selling Information The latest short interest is 21.77K, so 1.41% of the outstanding
shares have been sold short.
Short Interest 21.77K Short % of Shares Out 1.41% Short % of Float 1.5% Short Ratio (days to cover) 1.49
Valuation Ratios The PE ratio is -1.55 and the forward
PE ratio is -0.91.
Xenetic Biosciences's PEG ratio is
0.3.
PE Ratio -1.55 Forward PE -0.91 PS Ratio 2.46 Forward PS 1.6 PB Ratio 1.02 P/FCF Ratio -2.18 PEG Ratio 0.3
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Xenetic Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 7.37,
with a Debt / Equity ratio of 0.
Current Ratio 7.37 Quick Ratio 7.37 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.25M Profits Per Employee $-1.98M Employee Count 2 Asset Turnover 0.36 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -22.9% in the
last 52 weeks. The beta is 2.44, so Xenetic Biosciences's
price volatility has been higher than the market average.
Beta 2.44 52-Week Price Change -22.9% 50-Day Moving Average 3.32 200-Day Moving Average 3.49 Relative Strength Index (RSI) 51.81 Average Volume (20 Days) 80,351
Income Statement In the last 12 months, Xenetic Biosciences had revenue of 2.5M
and earned -3.96M
in profits. Earnings per share was -2.57.
Revenue 2.5M Gross Profit 2.5M Operating Income -4.2M Net Income -3.96M EBITDA -4.2M EBIT -4.2M Earnings Per Share (EPS) -2.57
Full Income Statement Balance Sheet The company has 6.17M in cash and 0 in
debt, giving a net cash position of 6.17M.
Cash & Cash Equivalents 6.17M Total Debt n/a Net Cash n/a Retained Earnings -197.19M Total Assets 5.35M Working Capital 4.45M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -2.82M
and capital expenditures 0, giving a free cash flow of -2.82M.
Operating Cash Flow -2.82M Capital Expenditures n/a Free Cash Flow -2.82M FCF Per Share -1.83
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -168.16% and -158.39%.
Gross Margin 100% Operating Margin -168.16% Pretax Margin -158.39% Profit Margin -158.39% EBITDA Margin -168.16% EBIT Margin -168.16% FCF Margin -112.69%
Dividends & Yields XBIO does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for XBIO.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on May 15, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date May 15, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -49.54 Piotroski F-Score 3
